BioNTech SE

BNTX

Company Profile

  • Business description

    BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

  • Contact

    An der Goldgrube 12
    MainzRPD-55131
    DEU

    T: +49 613190840

    E: [email protected]

    https://www.biontech.de

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6,772

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.3045.10-0.50%
CAC 407,834.5816.300.21%
DAX 4024,217.5078.43-0.32%
Dow JONES (US)44,901.92208.010.47%
FTSE 1009,120.3118.06-0.20%
HKSE25,388.35278.83-1.09%
NASDAQ21,108.3250.360.24%
Nikkei 22541,456.23370.11-0.88%
NZX 50 Index12,853.4648.330.38%
S&P 5006,388.6425.290.40%
S&P/ASX 2008,666.9042.50-0.49%
SSE Composite Index3,593.6612.07-0.33%

Market Movers